Effectiveness and Safety of the Coadministration of Rifampin and Warfarin versus Direct Oral Anticoagulants: A Cohort Study
Advances in Pharmacological and Pharmaceutical Sciences · 2024-01 · 2024 (1)
DOI: 10.1155/2024/9694592 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Advances in Pharmacological and Pharmaceutical Sciences, online erschienen am 25.09.2024. Verfasst von Ju-Chieh Wung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Taipei Veterans General Hospital, Taipei, Taiwan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Veterans General Hospital.
Abstract (Originalsprache)
Introduction
Pharmacokinetic studies have shown that rifampin reduces the levels of oral anticoagulants during the initiation of coadministration, raising concerns about an increased thrombotic risk, but there are limited comparative clinical outcomes between rifampin and warfarin compared with direct oral anticoagulants (DOACs). This study aimed to evaluate the effectiveness and safety of concurrent use of rifampin and warfarin versus DOACs, with assessments of outcome‐associated factors and oral anticoagulant (OAC) management quality.
Methods
A total of 142 patients given rifampin plus warfarin ( n = 56) or DOACs ( n = 86) for over 7 days were included, and their clinical data and outcomes were compared.
Results
The median Charlson Comorbidity Index and HAS‐BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score of the two groups were 2 and 3, respectively. The incidence rate of composite ischemic or thromboembolic events was 2.16 and 1.44 per 10,000 patient‐days in the warfarin and DOAC groups, respectively, with an adjusted hazard ratio (HR) of 0.41 (95% confidence interval [CI] 0.02–7.34). The incidence rate of composite major bleeding or clinically relevant nonmajor bleeding events was 1.58 and 1.52 per 10,000 patient‐days in the warfarin and DOAC groups, respectively, with an adjusted HR of 1.12 (95% CI 0.32–4.45). The risk of composite bleeding events increased with a higher HAS‐BLED score (HR: 1.62, 95% CI: 1.02–2.63). Moreover, 34.3% of warfarin users maintained a percent time in therapeutic range of above 50%. Furthermore, 77.9% of DOAC users received appropriate dosing.
Conclusion
No significant differences were observed in terms of the incidence of thrombotic or bleeding events between the two groups during coadministration. In addition, a higher HAS‐BLED score was associated with a greater risk of bleeding events regardless of the class of OACs used. Finally, close monitoring of bleeding events should be considered.
Autor:innen und Institutionen
- Department of Pharmacy Taipei Veterans General Hospital, Taipei, Taiwan.
- Department of Pharmacy College of Pharmaceutical Sciences National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Pharmacy National Taiwan University Hospital, Taipei, Taiwan.
- Institute of Public Health School of Medicine National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Heart Rhythm Center and Division of Cardiology, Department of Medicine Taipei Veterans General Hospital, Taipei, Taiwan.
- Department of Experimental Examination Healthcare and Services Center Taipei Veterans General Hospital, Taipei, Taiwan.
ORCID-Profile: Ju-Chieh Wung, Chia-Chieh Lin, Yuh-Lih Chang
Förderung
- Taipei Veterans General Hospital
Zitieren
APA
Wung, J. C., Hsu, C. C., Wang, C. E., Dong, Y. H., Lin, C. C., Wang, S. Y., Chang, S. L., & Chang, Y. L. (2024). Effectiveness and Safety of the Coadministration of Rifampin and Warfarin versus Direct Oral Anticoagulants: A Cohort Study. Advances in Pharmacological and Pharmaceutical Sciences, 2024(1). https://doi.org/10.1155/2024/9694592
Vancouver
Wung JC, Hsu CC, Wang CE, Dong YH, Lin CC, Wang SY, et al. Effectiveness and Safety of the Coadministration of Rifampin and Warfarin versus Direct Oral Anticoagulants: A Cohort Study. Advances in Pharmacological and Pharmaceutical Sciences. 2024;2024(1). doi:10.1155/2024/9694592
BibTeX
@article{Wung2024,
author = {Wung, Ju-Chieh and Hsu, Chia-Chen and Wang, Chi-En and Dong, Yaa-Hui and Lin, Chia-Chieh and Wang, Szu-Yu and Chang, Shih-Lin and Chang, Yuh-Lih},
title = {Effectiveness and Safety of the Coadministration of Rifampin and Warfarin versus Direct Oral Anticoagulants: A Cohort Study},
journal = {Advances in Pharmacological and Pharmaceutical Sciences},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/9694592}
}
EUVIMED